Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 107Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Leukemia 23Lymphoma 20Recurrence 16Burkitt Lymphoma 16Lymphoma, Mantle-Cell 13Neoplasms, Plasma Cell 11Lymphoma, Non-Hodgkin 11Waldenstrom Macroglobulinemia 9Lymphoma, Follicular 9Immunoglobulin Light-chain Amyloidosis 9Hodgkin Disease 9Breast Neoplasms 9Vomiting 8Neoplasms 8Nausea 8Lymphoma, B-Cell, Marginal Zone 8Lymphoma, Large B-Cell, Diffuse 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, T-Cell, Cutaneous 6Leukemia, Lymphocytic, Chronic, B-Cell 6Amyloidosis 6Leukemia, Myeloid, Acute 5Smoldering Multiple Myeloma 4Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, Large-Cell, Immunoblastic 4Lung Neoplasms 4Blast Crisis 4

Interventions

Lenalidomide 2Dexamethasone 2ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × POEMS Syndrome × Calcium Dobesilate × Clear all
NCT02921893 2025-02-12

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Mayo Clinic

Phase EARLY_PHASE1 Completed
21 enrolled
Plasma cell

Plasmacytoma, POEMS Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡